Gilead car-t therapy yescarta sales performance disclosure in 2019

Recently, Gilead announced the company's financial report revenue in 2019 According to the financial report information, the company's total revenue in 2019 was $22.4 billion, an increase of 1.5% compared with 2018 Specifically in the product field, Geely's car-t therapy yescarta obtained through the acquisition of kite achieved sales performance of $456 million in 2019, achieving a 72.7% growth rate compared with the sales performance of $264 million in 2018, which is also one of the products with the highest growth rate of performance except for HIV drug biktarvy For yescarta's significant growth performance, Geely said it was mainly due to the increase in the number of patients receiving the treatment and the continued expansion of the European market Yescarta was approved by the US FDA in 2017 It is mainly used to treat adult patients with specific type of large B-cell lymphoma who have received at least two or more other treatment schemes and have no effect or relapse It is the first car-t treatment for specific non Hodgkin's lymphoma approved by the US FDA It is also the successor of Novartis kymariah (tisagenlecleucel-t, ctl019) is the second car-t therapy approved for marketing In August 2018, yescarta was approved by the European Drug Administration (EMA) for marketing in Europe So far, yescarta and kymriah have not been approved for listing in China, but Fosun Kate, which is responsible for yescarta's industrialization in China (by Fosun Pharmaceutical and kit Pharma's joint venture in 2017, located in Zhangjiang Science City) announced in September 2018 that it had received approval from the State Drug Administration for the clinical trial of yescarta in the treatment of relapsed and refractory large B-cell lymphoma It is worth mentioning that in December 2019, Fosun Kate's first car-t industrial production base was officially opened in Zhangjiang, which will also boost the industrialization process of yescarta in China.